Riboflavin for COVID-19 Adjuvant Treatment in Patients With Mental Health Disorders: Observational Study

• Egile Nagusiak: R. A. Akasov (Egilea), E. V. Khaydukov (Egilea), D. S. Andreyuk (Egilea), N. V. Sholina (Egilea), A. N. Sheremeta (Egilea), D. V. Romanov (Egilea), G. P. Kostyuk (Egilea), V. Ya. Panchenko (Egilea), M. V. Kovalchuk (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: COVID-19 treatment remains a challenge for medicine because of the extremely short time for clinical studies of drug candidates, so the drug repurposing strategy, which implies the use of well-known and safe substances, is a promising approach.Objective: We present the results of an obse...